News

The topic of subject enrollment has been evaluated from many different perspectives.

After months of speculation about prospects for biosimilar development in the US, Novartis announced July 24 that FDA has accepted Sandoz' biologics license application ...

It's a given that events will happen during the course of the trial that will require not just new documents, but new sets of documents.

ESMO concerned that the proposed EU General Data Protection Regulation could make cancer research impossible and add a significant burden to cancer patients

ESMO is concerned that the proposed European Union General Data Protection Regulation could make cancer research impossible and add a significant burden to both doctors and cancer patients.

Expanding bio-risk management support for federal, state and institutional laboratories

Astra Nova Training and ACRES announced a strategic alliance collaboration

This article will discuss FDA's post-marketing surveillance programs, and how biopharmaceutical sponsors can work with the FDA to identify unreported Adverse Events.

Cognizant announced that it has been selected by TransCelerate BioPharma Inc. to develop a subscription-based platform

Astra Nova Training and ACRES announced a Strategic Alliance collaboration.

More attention is being paid to blood pressure effects in new chemical entities under development for non-hypertension indications.

Adds largest independent and only AAHRPP-accredited Canadian IRB/REB to the Chesapeake IRB organization

Combined Assets Expand Expertise and Reach

CTI Clinical Trial and Consulting Services announces that it has opened an office in S?o Paulo, Brazil

Chesapeake IRB has acquired Goodwyn IRB and IRB Services

CTI Clinical Trial and Consulting Services has opened an office in Sao Paulo, Brazil.

MCC has just published an executive summary of its Risk Based Monitoring Usage Survey.

One event which you may have missed at DIA was the launch of a new suite of eClinical solutions by Techorizon.

EMA has insisted that the concerns raised about its scientific advice given to pharmaceutical companies stem from a flawed understanding of the activities of the agency and its partners in this area.

A potential treatment for sickle cell disease has come through early stage development due to support from a collaborative partnership established by NCATS at the NIH.

WIRB-Copernicus Group announced that it has acquired Alliance Biosciences.

Dr. Paul Wicks, head of innovation at PatientsLikeMe, detailed for Applied Clinical Trials, the three services the company announced at DIA.

Bracket announced that Biotie Therapies has selected its CDR System for use as the primary endpoint for their Phase II trial.

Two experts have engaged in a lively debate about whether research fraud should be classed as a criminal act.

Chiltern and Ockham announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.

Chiltern and Ockham today announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.

Industry news focusing on the people and organizations who work in the clinical trials profession.

On thebmj.com today, two doctors debate whether research fraud should be classed as a criminal act.